The study, published in the journal Molecular Metabolism, has involved the participation of IDIBAPS researchers.
The goal of the project is to find out the critical factors that destabilise protein drugs during their handling at hospitals and patients’ homes.
The findings open a new conceptual framework to understand the striking context-dependent pharmacological actions of cannabis in the brain.
A trial carried out entirely in Catalonia has shown that therapy with dolutegravir plus lamivudine has an efficacy similar to that of triple therapy.1
The study, led by CIBERES, included the participation of IDIBAPS and was published in the Journal of Internal Medicine.
The transparency agreement on the use of animals in scientific experimentation in Spain is a document promoted by the Spanish Confederation of Scient1
A study by CIBERSAM with the participation of Hospital Clínic-IDIBAPS found that treatment-resistant depression has a mean incidence in Spain of 0.931
Researchers from the CLÍNIC-IDIBAPS, the Hospital Universitari Vall d’Hebron and the Parc Taulí de Sabadell have shown the damage caused by the SARS-1
The study, carried out by researchers from the IDIBAPS research group Transversal research in primary care, has been published in Annals of Family Me1
IDIBAPS management has approved the appointment of doctor Michela Bertero as the new IDIBAPS director of strategy. The decision was made following an1
